300181.SHE Zhejiang Jolly Pharmaceutical Co Ltd
- Market cap
- CNY 8.61B
- P/E
- 13.5x
- P/B
- 2.65x
- ROE
- 20.8%
- Dividend yield
- 4.92%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300181.SHE undervalued?
Graham number300181.SHE trades 26.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Jolly Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Jolly Pharmaceutical Co Ltd yet.
Zhejiang Jolly Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Jolly Pharmaceutical Co Ltd
Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People's Republic of China and internationally. The company offers Wuling capsule to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. It also provides Lingze tablet, which is used to …
Full company profileZhejiang Jolly Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Jolly Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 840M | 679M | 730M | 911M | 1.09B | 1.46B | 1.81B | 1.94B | 2.58B | 3.04B | 3.35B |
| Gross Profit | 500M | 437M | 452M | 581M | 728M | 1.04B | 1.27B | 1.33B | 1.56B | 1.87B | 2.06B |
| Operating Income | 58.1M | 51.8M | 31.3M | 29.3M | 110M | 225M | 337M | 449M | 609M | 797M | 834M |
| EBITDA | 102M | 102M | 79.8M | 95.9M | 171M | 278M | 378M | 483M | 658M | 851M | 801M |
| Net Income | 72.0M | 45.1M | 20.8M | 25.6M | 88.8M | 179M | 273M | 383M | 508M | 632M | 660M |
| EPS | 0.12 | 0.07 | 0.03 | 0.04 | 0.15 | 0.29 | 0.39 | 0.55 | 0.73 | 0.90 | 0.94 |
| Balance Sheet | |||||||||||
| Total Assets | 2.04B | 2.15B | 2.11B | 2.05B | 2.47B | 2.75B | 3.64B | 3.63B | 3.99B | 4.71B | 4.99B |
| Total Liabilities | 566M | 662M | 727M | 643M | 750M | 765M | 879M | 853M | 1.17B | 1.47B | 1.75B |
| Shareholders' Equity | 1.32B | 1.35B | 1.29B | 1.31B | 1.60B | 1.84B | 2.70B | 2.73B | 2.77B | 3.18B | 3.18B |
| Cash & Short-term Investments | 330M | 169M | 224M | 139M | 315M | 298M | 1.09B | 1.08B | 805M | 681M | 340M |
| Total Debt | 375M | 394M | 461M | 357M | 348M | 207M | 173M | 210M | 426M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 58.3M | 6.51M | 78.3M | 129M | 280M | 252M | 319M | 288M | 297M | 412M | - |
| Capital Expenditure | 143M | 124M | 154M | 40.5M | 58.4M | 148M | 178M | 132M | 263M | 287M | 129M |
| Free Cash Flow | -84.9M | -118M | -75.6M | 88.5M | 221M | 104M | 141M | 157M | 34.2M | 125M | 169M |
| Ratios | |||||||||||
| ROE | 5.4% | 3.3% | 1.6% | 2.0% | 5.5% | 9.7% | 10.1% | 14.0% | 18.3% | 19.9% | 20.8% |
| ROA | 3.5% | 2.1% | 1.0% | 1.2% | 3.6% | 6.5% | 7.5% | 10.6% | 12.7% | 13.4% | 13.2% |
| Net Profit Margin | 8.6% | 6.6% | 2.8% | 2.8% | 8.1% | 12.3% | 15.1% | 19.7% | 19.7% | 20.8% | 19.7% |
| Debt to Equity | 0.28x | 0.29x | 0.36x | 0.27x | 0.22x | 0.11x | 0.06x | 0.08x | 0.15x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Jolly Pharmaceutical Co Ltd dividends
- Dividend yield
- 4.92%
- Forward dividend
- 0.70 CNY
- Payout ratio
- 67.1%
- Ex-dividend date
- Sep 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 424M | 0.60 | 67.1% |
| 2024 | CNY 321M | 0.46 | 63.2% |
| 2023 | CNY 220M | 0.32 | 57.4% |
| 2022 | CNY 122M | 0.17 | 44.6% |
| 2021 | CNY 60.9M | 0.10 | 33.9% |
| 2020 | CNY 12.2M | 0.02 | 13.7% |
| 2019 | CNY 48.7M | 0.08 | 190.2% |
| 2018 | CNY 32.5M | 0.05 | 156.6% |
| 2017 | CNY 28.3M | 0.04 | 62.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 17:10 on May 20, 2015.
Who owns Zhejiang Jolly Pharmaceutical Co Ltd
- Insiders 27.28%
- Institutions 5.72%
- Public & others 67.01%
- Shares outstanding 701M
- Free float 541M
Zhejiang Jolly Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Jolly Pharmaceutical Co Ltd
- Ticker
- 300181.SHE
- ISIN
- CNE100001096
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Feb 22, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,861
- Fiscal year end
- December
- Address
- No. 388, Zhiyuan North Road, Huzhou, China, 313200
- Phone
- 86 57 2828 1088
- Website
- zuoli.com
About Zhejiang Jolly Pharmaceutical Co Ltd
Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People's Republic of China and internationally. The company offers Wuling capsule to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. It also provides Lingze tablet, which is used to treat frequent urination, dysuria, weak steam of urine, endless urine, and soreness and weakness of waist and knees caused by benign prostatic hyperplasia, kidney deficiency, and blood stasis; and Bailing tablet that is used as the adjuvant therapy to treat cough, asthma, back pain, and chronic bronchitis, which are caused by the deficiency of lungs and kidney. In addition, the company offers Linglianhua particles for the treatment of symptoms, including sweating, insomnia, dysphoria, heart palpitations, dreaminess, giddy tinnitus, lassitude in loin and legs, dry stool, and abnormal furred tongue, as well as weak pulse caused by perimenopausal syndrome, or disharmony of heart and kidney. Further, it provides azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside injections. Additionally, it offers materials, such as cephalosporin sinensis, fermented cordyceps, and Wuling powders. It invests and participates in the medical services of Deqing No.3 People's Hospital. The company was formerly known as Zhejiang Jolly Pharmaceutical Health Products Co., LTD. and changed its name to Zhejiang Jolly Pharmaceutical Co.,LTD in 1998. The company was founded in 1995 and is based in Huzhou, China.
Zhejiang Jolly Pharmaceutical Co Ltd management
8- Mr. Tao WangGM & Non-Independent Director · born 1968
- Ms. Li YeDeputy GM & Finance Director · born 1975
- Ms. Yuehong ShenDeputy GM & Non-Independent Director · born 1975
- Ms. Ying WuSecretary to the Board · born 1979
- Mr. Xiao Guo PengDeputy General Manager · born 1973
- Ms. Xin TanDeputy General Manager · born 1987
- Mr. Aihua MaDeputy General Manager · born 1966
- He LengHead of the Accounting Agency & Accounting Supervisor